We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

124 hedge funds and large institutions have $90.5M invested in Coherus Oncology in 2024 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 30 increasing their positions, 34 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,679% more call options, than puts

Call options by funds: $7.36M | Put options by funds: $154K

13% more capital invested

Capital invested by funds: $79.9M → $90.5M (+$10.6M)

3% less funds holding

Funds holding: 128 → 124 (-4)

9.85% less ownership

Funds ownership: 66.79% → 56.94% (-9.8%)

11% less first-time investments, than exits

New positions opened: 31 | Existing positions closed: 35

12% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 34

Holders
124
Holders Change
-4
Holders Change %
-3.13%
% of All Funds
1.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
31
Increased
30
Reduced
34
Closed
35
Calls
$7.36M
Puts
$154K
Net Calls
+$7.21M
Net Calls Change
+$7.2M

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$5.93M
2
TCM
Tang Capital Management
California
+$1.46M
3
Morgan Stanley
Morgan Stanley
New York
+$1.44M
4
UBS Group
UBS Group
Switzerland
+$601K
5
Millennium Management
Millennium Management
New York
+$283K

Top Sellers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
-$5.77M
2
Citadel Advisors
Citadel Advisors
Florida
-$3.21M
3
Barclays
Barclays
United Kingdom
-$2.43M
4
Goldman Sachs
Goldman Sachs
New York
-$1.73M
5
BlackRock
BlackRock
New York
-$983K
Name Holding Trade Value Shares
Change 		Change in
Stake
JFG
26
Jefferies Financial Group
New York
$425K +$28K +25,000 +9%
Barclays
27
Barclays
United Kingdom
$414K -$2.43M -2,166,113 -88%
TWP
28
Tyche Wealth Partners
Texas
$368K +$57.1K +50,864 +24%
SCM
29
Stonepine Capital Management
Oregon
$345K +$280K +250,000 New
BCM
30
Bridgeway Capital Management
Texas
$280K -$123K -109,700 -35%
AllianceBernstein
31
AllianceBernstein
Tennessee
$260K – – –
RhumbLine Advisers
32
RhumbLine Advisers
Massachusetts
$214K +$6.38K +5,692 +4%
Bank of America
33
Bank of America
North Carolina
$212K -$570K -508,348 -77%
Two Sigma Investments
34
Two Sigma Investments
New York
$185K -$615K -548,242 -80%
GCP
35
GSA Capital Partners
United Kingdom
$170K +$138K +123,022 New
SOW
36
State of Wyoming
Wyoming
$165K +$50.9K +45,405 +61%
HSBC Holdings
37
HSBC Holdings
United Kingdom
$149K +$4.25K +3,785 +4%
N
38
Nuveen
North Carolina
$131K – – –
SC
39
Savant Capital
Illinois
$130K +$105K +93,984 New
BC
40
Birchview Capital
Vermont
$113K -$325K -290,000 -78%
GCM
41
Graham Capital Management
Connecticut
$105K +$8.58K +7,649 +11%
MIM
42
MetLife Investment Management
New Jersey
$101K +$82K +73,099 New
SW
43
SteelPeak Wealth
California
$95.2K – – –
Invesco
44
Invesco
Georgia
$91.2K +$5.41K +4,822 +8%
LPL Financial
45
LPL Financial
California
$89.4K -$32.9K -29,321 -31%
Mirae Asset Global ETFs Holdings
46
Mirae Asset Global ETFs Holdings
Hong Kong
$88.1K +$4.68K +4,171 +7%
Wells Fargo
47
Wells Fargo
California
$85.3K +$17K +15,137 +32%
CF
48
Corebridge Financial
Texas
$76.3K -$4.68K -4,176 -7%
WG
49
Wealth Group
North Carolina
$72K – – –
Corient Private Wealth
50
Corient Private Wealth
Florida
$69K – – –
1
2
3 4 5

CHRS Hedge Fund Activity: Q4 2024 in Review

124 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q4 2024, worth a combined $90.5M — up 13% from $79.9M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of CHRS and 31 opened new positions — a net loss of 4 holders — while 34 trimmed existing stakes and 30 added.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $5.93M. The largest seller was Rubric Capital Management (New York), cutting an estimated $5.77M.

  • 124 institutional investors held Coherus Oncology (CHRS) as of Q4 2024, down from 128 in Q3 2024.
  • Funds reported $90.5M of Coherus Oncology stock for Q4 2024, up 13% quarter-over-quarter.
  • 31 funds opened new Coherus Oncology positions in Q4 2024 and 35 closed out, a net change of -4 holders.
  • The largest Coherus Oncology buyer in Q4 2024 was Point72 Asset Management, an estimated $5.93M added.
  • The largest Coherus Oncology seller in Q4 2024 was Rubric Capital Management (New York), an estimated $5.77M sold.

Based on aggregated 13F filings for Q4 2024.